pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
pellepharm PRESS RELEASE ARCHIVE
Oct 29, 2020
PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology
Jan 8, 2020
PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
Dec 2, 2019
PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
Apr 1, 2019
PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
Jan 31, 2019
Phyton Biotech Partners with PellePharm to Develop Renewable Supply of Cyclopamine for Investigational Topical Cancer Therapy
Nov 21, 2018
PellePharm to Present at Piper Jaffray Healthcare Conference
Nov 20, 2018
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases
Nov 20, 2018
LEO Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases
Oct 15, 2018
PellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCs
Sep 25, 2018
PellePharm to Present at Cantor Fitzgerald Global Healthcare Conference
Jun 13, 2018
PellePharm to Participate in the Cantor Fitzgerald Dermatology and Aesthetics Summit
May 21, 2018
PellePharm to Present at the 2018 UBS Global Healthcare Conference
May 16, 2018
PellePharm to Present Topical Patidegib and Skin Cancer Epidemiological Data at the 7th International Investigative Dermatology Meeting
Jan 4, 2018
PellePharm Appoints Sanuj K. Ravindran, M.D., as President and Chief Executive Officer
Nov 20, 2017
FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to PellePharm for Topical Patidegib in Gorlin Syndrome
Jul 31, 2017
PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas and Third Closing of a $20 Million Series B Financing
Dec 8, 2016
PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
